PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9022961-5	1997	In addition, 2 ml of human growth hormone (1 mg ml-1) were associated with BCP powder by physical adsorption on bead surfaces before compaction.	hydroxyapatite-beta tricalcium phosphate	75-78	growth hormone 1	Homo sapiens	27-44
11077412-2	2001	BCP ceramics impregnated with different doses of recombinant human bone morphogenetic protein 2 (rhBMP-2) (1, 5, and 10 microg) were used for experimental purposes and ceramics without rhBMP-2 were used for control.	hydroxyapatite-beta tricalcium phosphate	0-3	bone morphogenetic protein 2	Homo sapiens	67-95
34110599-0	2021	Investigation into the effects of leukemia inhibitory factor on the bone repair capacity of BMSCs-loaded BCP scaffolds in the mouse calvarial bone defect model.	hydroxyapatite-beta tricalcium phosphate	105-108	leukemia inhibitory factor	Mus musculus	34-60
33819813-1	2021	This study aimed to fabricate a multi-layered biphasic calcium phosphate (BCP) platform for programmed bone morphogenetic protein-2 (BMP-2) release, which means to block the initial burst release and promote releasing during the differentiation phase of osteogenic cells.	hydroxyapatite-beta tricalcium phosphate	74-77	bone morphogenetic protein 2	Homo sapiens	103-131
33819813-1	2021	This study aimed to fabricate a multi-layered biphasic calcium phosphate (BCP) platform for programmed bone morphogenetic protein-2 (BMP-2) release, which means to block the initial burst release and promote releasing during the differentiation phase of osteogenic cells.	hydroxyapatite-beta tricalcium phosphate	74-77	bone morphogenetic protein 2	Homo sapiens	133-138
34110599-2	2021	In the present study, we examined the in vitro effects of LIF on osteoblast differentiation of bone marrow stem cells (BMSCs) and explored in vivo effects of LIF on the bone repair capacity of BMSCs-loaded biphasic calcium phosphate (BCP) scaffolds in mouse calvarial bone defect model.	hydroxyapatite-beta tricalcium phosphate	234-237	leukemia inhibitory factor	Mus musculus	158-161
34110599-8	2021	The in vivo studies showed that implantation of Lif-overexpressing BMSCs-loaded BCP scaffolds significantly increased the bone volume and bone density at 4 and 8 weeks after transplantation, and promoted the regeneration of bone tissues in the mouse calvarial bone defect at 8 weeks after transplantation when compared to the BMSCs-loaded BCP scaffolds group; while Lif-silencing BMSCs-loaded BCP scaffolds had the opposite effects.	hydroxyapatite-beta tricalcium phosphate	393-396	leukemia inhibitory factor	Mus musculus	366-369
34110599-9	2021	The present study for the first time demonstrated that LIF promoted the in vitro osteoblast differentiation of hypoxia-treated BMSCs; and further studies revealed that LIF exerted enhanced effects on the bone repair capacity of BMSCs-load BCP scaffolds in mouse calvarial bone defect model.	hydroxyapatite-beta tricalcium phosphate	239-242	leukemia inhibitory factor	Mus musculus	55-58
34110599-9	2021	The present study for the first time demonstrated that LIF promoted the in vitro osteoblast differentiation of hypoxia-treated BMSCs; and further studies revealed that LIF exerted enhanced effects on the bone repair capacity of BMSCs-load BCP scaffolds in mouse calvarial bone defect model.	hydroxyapatite-beta tricalcium phosphate	239-242	leukemia inhibitory factor	Mus musculus	168-171
34191473-0	2021	eIF2alpha-ATF4 Pathway Activated by a Change in the Calcium Environment Participates in BCP-Mediated Bone Regeneration.	hydroxyapatite-beta tricalcium phosphate	88-91	eukaryotic translation initiation factor 2A	Rattus norvegicus	0-9
34191473-0	2021	eIF2alpha-ATF4 Pathway Activated by a Change in the Calcium Environment Participates in BCP-Mediated Bone Regeneration.	hydroxyapatite-beta tricalcium phosphate	88-91	activating transcription factor 4	Rattus norvegicus	10-14
34191473-3	2021	Endoplasmic reticulum stress (ERs) and the subsequent PERK-eIF2alpha-ATF4 pathway can be activated by various factors, including trauma and intracellular calcium changes, and therefore worth exploring as a potential mechanism in BCP-mediated bone repair.	hydroxyapatite-beta tricalcium phosphate	229-232	eukaryotic translation initiation factor 2A	Rattus norvegicus	59-68
34191473-3	2021	Endoplasmic reticulum stress (ERs) and the subsequent PERK-eIF2alpha-ATF4 pathway can be activated by various factors, including trauma and intracellular calcium changes, and therefore worth exploring as a potential mechanism in BCP-mediated bone repair.	hydroxyapatite-beta tricalcium phosphate	229-232	activating transcription factor 4	Rattus norvegicus	69-73
34191473-6	2021	The results showed that the ERs and eIF2alpha-ATF4 pathway activation were observed during 4 weeks of bone repair, with a rapid but brief increase immediately after artificial defect surgery and a re-increase after 4 weeks with the resorption of BCP materials.	hydroxyapatite-beta tricalcium phosphate	246-249	eukaryotic translation initiation factor 2A	Rattus norvegicus	36-45
34191473-6	2021	The results showed that the ERs and eIF2alpha-ATF4 pathway activation were observed during 4 weeks of bone repair, with a rapid but brief increase immediately after artificial defect surgery and a re-increase after 4 weeks with the resorption of BCP materials.	hydroxyapatite-beta tricalcium phosphate	246-249	activating transcription factor 4	Rattus norvegicus	46-50
34191473-7	2021	Mild ERs and the activated eIF2alpha induced by the calcium changes mediated by BCP regulated the expression of osteogenic-related proteins and had an important role during the defect repair.	hydroxyapatite-beta tricalcium phosphate	80-83	eukaryotic translation initiation factor 2A	Rattus norvegicus	27-36
34191473-8	2021	In conclusion, the eIF2alpha-ATF4 pathway activated by a change in the calcium environment participates in BCP-mediated bone regeneration.	hydroxyapatite-beta tricalcium phosphate	107-110	eukaryotic translation initiation factor 2A	Rattus norvegicus	19-28
34191473-8	2021	In conclusion, the eIF2alpha-ATF4 pathway activated by a change in the calcium environment participates in BCP-mediated bone regeneration.	hydroxyapatite-beta tricalcium phosphate	107-110	activating transcription factor 4	Rattus norvegicus	29-33
35407901-10	2022	ALP staining further showed conditioned media from L929 fibroblasts treated by BCP could enhance osteogenic differentiation of BMSCs.	hydroxyapatite-beta tricalcium phosphate	79-82	alopecia, recessive	Mus musculus	0-3
33831568-6	2021	We also highlighted the key role of the LBP/CD14 proteins in the TLR4 activation of blood cells by BCP particles.	hydroxyapatite-beta tricalcium phosphate	99-102	toll like receptor 4	Homo sapiens	65-69
33831568-13	2021	Here, using proteomic analyses we showed that the osteogenic properties of 80-200 microm BCP particles embedded in a blood clot is associated with a higher expression of fibrinogen.	hydroxyapatite-beta tricalcium phosphate	89-92	fibrinogen beta chain	Homo sapiens	170-180
33831568-6	2021	We also highlighted the key role of the LBP/CD14 proteins in the TLR4 activation of blood cells by BCP particles.	hydroxyapatite-beta tricalcium phosphate	99-102	lipopolysaccharide binding protein	Homo sapiens	40-43
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	fibrinogen beta chain	Homo sapiens	0-10
33831568-6	2021	We also highlighted the key role of the LBP/CD14 proteins in the TLR4 activation of blood cells by BCP particles.	hydroxyapatite-beta tricalcium phosphate	99-102	CD14 molecule	Homo sapiens	44-48
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	27-32
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	toll like receptor 4	Homo sapiens	58-62
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	toll like receptor 4	Homo sapiens	103-107
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	lipopolysaccharide binding protein	Homo sapiens	138-141
33831568-14	2021	Fibrinogen upregulates the Myd88- and NF-kappaB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.	hydroxyapatite-beta tricalcium phosphate	91-94	CD14 molecule	Homo sapiens	146-150
31098332-1	2019	Purpose: The aim of this study was to evaluate the enhancement of osteogenic potential of biphasic calcium phosphate (BCP) bone substitute coated with Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) and epigallocatechin-3-gallate (EGCG).	hydroxyapatite-beta tricalcium phosphate	118-121	bone morphogenetic protein 2	Homo sapiens	194-222
33456309-5	2021	Then, the in vitro cell adhesion, proliferation and alkaline  phosphatase (ALP) activity of bone marrow stromal cells (BMSCs) on the BCP ceramics were evaluated.	hydroxyapatite-beta tricalcium phosphate	133-136	alkaline phosphatase, placental	Homo sapiens	75-78
32614486-9	2020	Similar 18F-NaF tracer uptake patterns were observed between 3 and 12 weeks for the BCP-coated TPU and titanium implants, but not for the uncoated implants.	hydroxyapatite-beta tricalcium phosphate	84-87	C-X-C motif chemokine ligand 8	Homo sapiens	12-15
26510170-3	2016	PURPOSE: The aim of the present study was to assess whether the combination of BMP2 with this novel Biphasic Calcium Phosphate (BCP) scaffold may additionally promote new bone regeneration.	hydroxyapatite-beta tricalcium phosphate	128-131	bone morphogenetic protein 2	Rattus norvegicus	79-83
29977596-4	2018	Besides, by directly culturing BMSCs on BCP ceramic discs under both in vitro and in vivo physiological environment, it was found that the differentiation of BMSCs toward vascular endothelial cells (VECs) happened under the stimulation of BCP ceramic, as was confirmed by the up-regulated gene expressions and protein secretions of VECs-related characteristic factors, including kinase insert domain receptor, von willebrand factor, vascular cell adhesion molecule-1 and cadherin 5 in the BMSCs.	hydroxyapatite-beta tricalcium phosphate	239-242	cadherin 5	Homo sapiens	471-481
28701073-1	2018	The purposes of this study are to confirm the role of Fibroblast Growth Factor-2 (FGF-2) in bone regeneration by adding various concentrations of FGF-2 to the collagen membrane and applying it to the Biphasic Calcium Phosphate (BCP) bone graft site for guided bone regeneration, to explore the potential of collagen membrane as FGF-2 carrier, and to determine the optimum FGF concentration for enhancement of bone regeneration.	hydroxyapatite-beta tricalcium phosphate	228-231	fibroblast growth factor 2	Oryctolagus cuniculus	54-80
28701073-1	2018	The purposes of this study are to confirm the role of Fibroblast Growth Factor-2 (FGF-2) in bone regeneration by adding various concentrations of FGF-2 to the collagen membrane and applying it to the Biphasic Calcium Phosphate (BCP) bone graft site for guided bone regeneration, to explore the potential of collagen membrane as FGF-2 carrier, and to determine the optimum FGF concentration for enhancement of bone regeneration.	hydroxyapatite-beta tricalcium phosphate	228-231	fibroblast growth factor 2	Oryctolagus cuniculus	82-87
28599183-10	2017	These biocompatible BCP microspheres were highly effective in loading and prolonged release of both small molecule [dexamethasone (Dex)] and protein [bovine serum albumin (BSA)] models.	hydroxyapatite-beta tricalcium phosphate	20-23	albumin	Homo sapiens	157-170
29240243-8	2018	Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds.	hydroxyapatite-beta tricalcium phosphate	81-84	bone morphogenetic protein 2	Homo sapiens	172-198
29240243-8	2018	Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds.	hydroxyapatite-beta tricalcium phosphate	81-84	bone morphogenetic protein 2	Homo sapiens	200-205
29240243-8	2018	Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds.	hydroxyapatite-beta tricalcium phosphate	224-227	bone morphogenetic protein 2	Homo sapiens	172-198
29240243-8	2018	Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds.	hydroxyapatite-beta tricalcium phosphate	224-227	bone morphogenetic protein 2	Homo sapiens	200-205
28528118-0	2017	Calcium supplementation decreases BCP-induced inflammatory processes in blood cells through the NLRP3 inflammasome down-regulation.	hydroxyapatite-beta tricalcium phosphate	34-37	NLR family pyrin domain containing 3	Homo sapiens	96-101
28528118-7	2017	Our results strongly suggest that the anti-inflammatory property of calcium supplemented-BCP results from its down-modulating effect on P2X7R gene expression and its capacity to inhibit ATP/P2X7R interactions, decreasing the NLRP3 inflammasome activation.	hydroxyapatite-beta tricalcium phosphate	89-92	NLR family pyrin domain containing 3	Homo sapiens	225-230
28740783-8	2017	Degradation of HA and BCP was enhanced in the presence of BMP-7 (P = 0.001).	hydroxyapatite-beta tricalcium phosphate	22-25	bone morphogenetic protein 7	Homo sapiens	58-63
28740783-11	2017	CONCLUSIONS: BMP-7 enhanced bone formation and degradation of HA and BCP ceramics via osteoclast resorption.	hydroxyapatite-beta tricalcium phosphate	69-72	bone morphogenetic protein 7	Homo sapiens	13-18
28740783-14	2017	Novel degradable HA and BCP ceramics in the presence of BMP-7 are promising bone substitutes in the growing individual.	hydroxyapatite-beta tricalcium phosphate	24-27	bone morphogenetic protein 7	Homo sapiens	56-61
27771827-0	2017	Recombinant human bone morphogenetic protein (rhBMP)9 induces osteoblast differentiation when combined with demineralized freeze-dried bone allografts (DFDBAs) or biphasic calcium phosphate (BCP).	hydroxyapatite-beta tricalcium phosphate	191-194	bone morphogenetic protein 1	Homo sapiens	18-44
28126596-3	2017	The results of cellular experiments confirmed that the gene expression of most inflammatory factors (IL-1, IL-6 and MCP-1) and growth factors (VEGF, PDGF and EGF) by macrophages were up-regulated to varying degrees by BCP ceramic and its degradation products.	hydroxyapatite-beta tricalcium phosphate	218-221	interleukin 1 alpha	Homo sapiens	101-105
28126596-3	2017	The results of cellular experiments confirmed that the gene expression of most inflammatory factors (IL-1, IL-6 and MCP-1) and growth factors (VEGF, PDGF and EGF) by macrophages were up-regulated to varying degrees by BCP ceramic and its degradation products.	hydroxyapatite-beta tricalcium phosphate	218-221	interleukin 6	Homo sapiens	107-111
28126596-3	2017	The results of cellular experiments confirmed that the gene expression of most inflammatory factors (IL-1, IL-6 and MCP-1) and growth factors (VEGF, PDGF and EGF) by macrophages were up-regulated to varying degrees by BCP ceramic and its degradation products.	hydroxyapatite-beta tricalcium phosphate	218-221	C-C motif chemokine ligand 2	Homo sapiens	116-121
28126596-3	2017	The results of cellular experiments confirmed that the gene expression of most inflammatory factors (IL-1, IL-6 and MCP-1) and growth factors (VEGF, PDGF and EGF) by macrophages were up-regulated to varying degrees by BCP ceramic and its degradation products.	hydroxyapatite-beta tricalcium phosphate	218-221	vascular endothelial growth factor A	Homo sapiens	143-147
28458969-8	2017	BMP-7 enhanced ceramic degradation in TCP (P = 0.05) and BCP (P = 0.05) implants but not in HA implants.	hydroxyapatite-beta tricalcium phosphate	57-60	bone morphogenetic protein 7	Homo sapiens	0-5
26970206-3	2017	In this study, we hypothesized that BMP2-cop.BioCaP could introduce osteoinductivity to BCP and so could function as effectively as autologous bone for the repair of a critical-sized bone defect.	hydroxyapatite-beta tricalcium phosphate	88-91	bone morphogenetic protein 2	Rattus norvegicus	36-40
26970206-9	2017	RESULTS: The combined application of BCP and BMP2-cop.BioCaP resulted in significantly more new bone formation than BCP alone.	hydroxyapatite-beta tricalcium phosphate	116-119	bone morphogenetic protein 2	Rattus norvegicus	45-49
26970206-11	2017	Compared with BCP alone, significantly more BCP degradation was found when mixed with BMP2-cop.BioCaP.	hydroxyapatite-beta tricalcium phosphate	44-47	bone morphogenetic protein 2	Rattus norvegicus	86-90
26510170-7	2016	The release kinetics of BMP2 from both BCP and collagen scaffolds was investigated over a 14-day period.	hydroxyapatite-beta tricalcium phosphate	39-42	bone morphogenetic protein 2	Rattus norvegicus	24-28
26510170-8	2016	RESULTS: The results from present study demonstrate that BMP2 is able to promote new bone formation in a concentration dependant manner when loaded with either a collagen scaffolds or BCP scaffolds.	hydroxyapatite-beta tricalcium phosphate	184-187	bone morphogenetic protein 2	Rattus norvegicus	57-61
26510170-11	2016	The release of BMP2 over time was rapidly released after 1 day on BCP scaffolds whereas a gradually release over time was observed for collagen scaffolds up to 14 days.	hydroxyapatite-beta tricalcium phosphate	66-69	bone morphogenetic protein 2	Rattus norvegicus	15-19
26510170-12	2016	CONCLUSION: The osteoinductive properties of BMP2 may further be enhanced by its combination with a novel synthetically fabricated osteoinductive BCP scaffold.	hydroxyapatite-beta tricalcium phosphate	146-149	bone morphogenetic protein 2	Rattus norvegicus	45-49
27485617-8	2016	In addition, the combination of rhBMP2 with BCP significantly improved ALP activity at 7 and 14 days post seeding, alizarin red staining at 14 days, and mRNA levels of Runx2, ALP and osteocalcin when compared to cells seeded with rhBMP2 alone or BCP alone.	hydroxyapatite-beta tricalcium phosphate	44-47	alkaline phosphatase, placental	Homo sapiens	71-74
27800217-9	2016	CONCLUSIONS: Within the limitations of this study, it can be suggested that a minimal concentration of BMP-2 (0.05 mg/mL) had an osteoinductive effect with accelerated mineralization in a rabbit sinus model using a BCP carrier.	hydroxyapatite-beta tricalcium phosphate	215-218	bone morphogenetic protein 2	Oryctolagus cuniculus	103-108
25675839-1	2016	OBJECTIVES: This study compared the bone regenerative effects of a recombinant human bone morphogenetic protein 2 (rhBMP-2)-loaded collagen-based biphasic calcium phosphate composite (BCPC) and rhBMP-2-loaded biphasic calcium phosphate (BCP).	hydroxyapatite-beta tricalcium phosphate	184-187	bone morphogenetic protein 2	Homo sapiens	85-113
26814714-11	2016	CLINICAL RELEVANCE: Novel BCP scaffolds are able to induce ectopic bone formation without the use of osteoinductive growth factors such as BMP2 and thus demonstrate a large clinical possibility to further enhance bone formation for a variety of clinical procedures.	hydroxyapatite-beta tricalcium phosphate	26-29	bone morphogenetic protein 2	Rattus norvegicus	139-143
27711142-0	2016	A Study of BMP-2-Loaded Bipotential Electrolytic Complex around a Biphasic Calcium Phosphate-Derived (BCP) Scaffold for Repair of Large Segmental Bone Defect.	hydroxyapatite-beta tricalcium phosphate	102-105	bone morphogenetic protein 2	Oryctolagus cuniculus	11-16
27485617-8	2016	In addition, the combination of rhBMP2 with BCP significantly improved ALP activity at 7 and 14 days post seeding, alizarin red staining at 14 days, and mRNA levels of Runx2, ALP and osteocalcin when compared to cells seeded with rhBMP2 alone or BCP alone.	hydroxyapatite-beta tricalcium phosphate	44-47	RUNX family transcription factor 2	Homo sapiens	168-173
27485617-8	2016	In addition, the combination of rhBMP2 with BCP significantly improved ALP activity at 7 and 14 days post seeding, alizarin red staining at 14 days, and mRNA levels of Runx2, ALP and osteocalcin when compared to cells seeded with rhBMP2 alone or BCP alone.	hydroxyapatite-beta tricalcium phosphate	44-47	alkaline phosphatase, placental	Homo sapiens	175-178
27485617-8	2016	In addition, the combination of rhBMP2 with BCP significantly improved ALP activity at 7 and 14 days post seeding, alizarin red staining at 14 days, and mRNA levels of Runx2, ALP and osteocalcin when compared to cells seeded with rhBMP2 alone or BCP alone.	hydroxyapatite-beta tricalcium phosphate	44-47	bone gamma-carboxyglutamate protein	Homo sapiens	183-194
26561810-4	2015	The in vitro studies showed that sustained release of Aln from the BCP scaffolds consisted of porous microstructures, and revealed that MG-63 cells cultured on Aln-loaded BCP scaffolds showed significantly increased ALP activity, calcium deposition, and gene expression compared to cells cultured on BCP scaffolds.	hydroxyapatite-beta tricalcium phosphate	171-174	alkaline phosphatase, placental	Homo sapiens	216-219
32263223-6	2016	Moreover, western blotting analysis indicated that BCP ceramics could activate down-stream MAPK signaling pathways, whereas blockage of either ERK or P38 signals could dramatically attenuate BCP-induced osteogenesis.	hydroxyapatite-beta tricalcium phosphate	191-194	mitogen-activated protein kinase 1	Homo sapiens	143-146
32263223-6	2016	Moreover, western blotting analysis indicated that BCP ceramics could activate down-stream MAPK signaling pathways, whereas blockage of either ERK or P38 signals could dramatically attenuate BCP-induced osteogenesis.	hydroxyapatite-beta tricalcium phosphate	191-194	mitogen-activated protein kinase 14	Homo sapiens	150-153
27815469-8	2016	From these results, it can be concluded that BMP2 activated BCP for the enhancement of bone regeneration.	hydroxyapatite-beta tricalcium phosphate	60-63	bone morphogenetic protein 2	Homo sapiens	45-49
26606286-1	2016	PURPOSE: The aim of this study was to characterize the healing in rabbit calvarial bone defects after delivery of limited-dose (1.5 mug) Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2), and evaluate biphasic calcium phosphate (BCP) as a carrier.	hydroxyapatite-beta tricalcium phosphate	262-265	bone morphogenetic protein 2	Homo sapiens	180-208
26561810-4	2015	The in vitro studies showed that sustained release of Aln from the BCP scaffolds consisted of porous microstructures, and revealed that MG-63 cells cultured on Aln-loaded BCP scaffolds showed significantly increased ALP activity, calcium deposition, and gene expression compared to cells cultured on BCP scaffolds.	hydroxyapatite-beta tricalcium phosphate	171-174	alkaline phosphatase, placental	Homo sapiens	216-219
26193362-6	2015	We found that BCPs with low percentage of HA favored the expression of positive coupling factors, including sphingosine-kinase 1 (SPHK1) and collagen triple helix repeat containing 1 (Cthrc1).	hydroxyapatite-beta tricalcium phosphate	14-18	sphingosine kinase 1	Homo sapiens	108-128
24888232-2	2015	This study aimed at improving the fibrin-clotting rate by coating the surface of biphasic calcium phosphate (BCP) granules with fibrinogen (FNG).	hydroxyapatite-beta tricalcium phosphate	109-112	fibrinogen beta chain	Homo sapiens	128-138
24888232-2	2015	This study aimed at improving the fibrin-clotting rate by coating the surface of biphasic calcium phosphate (BCP) granules with fibrinogen (FNG).	hydroxyapatite-beta tricalcium phosphate	109-112	fibrinogen beta chain	Homo sapiens	140-143
24888232-3	2015	METHODS AND MATERIALS: FNG was coated on the BCP surface using an adsorption and freeze-drying method.	hydroxyapatite-beta tricalcium phosphate	45-48	fibrinogen beta chain	Homo sapiens	23-26
24888232-4	2015	The surface morphology of FNG-adsorbed BCP (FNG-BCP) was characterized using scanning electron microscopy (SEM), and the stability of the adsorbed FNG evaluated by gel electrophoresis and circular dichroism (CD) analysis.	hydroxyapatite-beta tricalcium phosphate	39-42	fibrinogen beta chain	Homo sapiens	26-29
24888232-4	2015	The surface morphology of FNG-adsorbed BCP (FNG-BCP) was characterized using scanning electron microscopy (SEM), and the stability of the adsorbed FNG evaluated by gel electrophoresis and circular dichroism (CD) analysis.	hydroxyapatite-beta tricalcium phosphate	39-42	fibrinogen beta chain	Homo sapiens	44-47
24888232-4	2015	The surface morphology of FNG-adsorbed BCP (FNG-BCP) was characterized using scanning electron microscopy (SEM), and the stability of the adsorbed FNG evaluated by gel electrophoresis and circular dichroism (CD) analysis.	hydroxyapatite-beta tricalcium phosphate	39-42	fibrinogen beta chain	Homo sapiens	44-47
24888232-6	2015	RESULTS: SEM studies showed numerous irregularly distributed FNG fractions adsorbed onto the surface of BCP granules.	hydroxyapatite-beta tricalcium phosphate	104-107	fibrinogen beta chain	Homo sapiens	61-64
26622495-6	2015	In the presence and absence of osteogenic inducers, the ALP activity of hPDLCs within BCP scaffolds was suppressed in varying degrees at all time-points.	hydroxyapatite-beta tricalcium phosphate	86-89	alkaline phosphatase, placental	Homo sapiens	56-59
26193362-6	2015	We found that BCPs with low percentage of HA favored the expression of positive coupling factors, including sphingosine-kinase 1 (SPHK1) and collagen triple helix repeat containing 1 (Cthrc1).	hydroxyapatite-beta tricalcium phosphate	14-18	sphingosine kinase 1	Homo sapiens	130-135
26193362-6	2015	We found that BCPs with low percentage of HA favored the expression of positive coupling factors, including sphingosine-kinase 1 (SPHK1) and collagen triple helix repeat containing 1 (Cthrc1).	hydroxyapatite-beta tricalcium phosphate	14-18	collagen triple helix repeat containing 1	Homo sapiens	141-182
26193362-6	2015	We found that BCPs with low percentage of HA favored the expression of positive coupling factors, including sphingosine-kinase 1 (SPHK1) and collagen triple helix repeat containing 1 (Cthrc1).	hydroxyapatite-beta tricalcium phosphate	14-18	collagen triple helix repeat containing 1	Homo sapiens	184-190
26179165-12	2015	In addition, MSCs cultured in BCP hybrid scaffolds produced more messenger RNA (mRNA) for osteopontin, osteocalcin, Runx2, and leptin receptor (leptin-R) than those cultured in coralline HA hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	30-33	osteopontin	Oryctolagus cuniculus	90-101
26179165-12	2015	In addition, MSCs cultured in BCP hybrid scaffolds produced more messenger RNA (mRNA) for osteopontin, osteocalcin, Runx2, and leptin receptor (leptin-R) than those cultured in coralline HA hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	30-33	osteocalcin	Oryctolagus cuniculus	103-114
26179165-12	2015	In addition, MSCs cultured in BCP hybrid scaffolds produced more messenger RNA (mRNA) for osteopontin, osteocalcin, Runx2, and leptin receptor (leptin-R) than those cultured in coralline HA hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	30-33	runt-related transcription factor 2	Oryctolagus cuniculus	116-121
26179165-12	2015	In addition, MSCs cultured in BCP hybrid scaffolds produced more messenger RNA (mRNA) for osteopontin, osteocalcin, Runx2, and leptin receptor (leptin-R) than those cultured in coralline HA hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	30-33	leptin receptor	Oryctolagus cuniculus	127-152
26179165-13	2015	Western blotting showed more Runx2 and leptin-R protein expression in BCP hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	70-73	runt-related transcription factor 2	Oryctolagus cuniculus	29-34
26179165-13	2015	Western blotting showed more Runx2 and leptin-R protein expression in BCP hybrid scaffolds.	hydroxyapatite-beta tricalcium phosphate	70-73	leptin receptor	Oryctolagus cuniculus	39-47
25808925-4	2015	A biphasic calcium phosphate (BCP)-NC-BMP2-VEGF (BNBV) scaffold was fabricated for this purpose.	hydroxyapatite-beta tricalcium phosphate	30-33	bone morphogenetic protein 2	Rattus norvegicus	38-42
25808925-4	2015	A biphasic calcium phosphate (BCP)-NC-BMP2-VEGF (BNBV) scaffold was fabricated for this purpose.	hydroxyapatite-beta tricalcium phosphate	30-33	vascular endothelial growth factor A	Rattus norvegicus	43-47
25808925-5	2015	The sponge BCP scaffold was prepared by replica method and then loaded with 0.5% NC containing BMP2-VEGF.	hydroxyapatite-beta tricalcium phosphate	11-14	bone morphogenetic protein 2	Rattus norvegicus	95-99
26179165-16	2015	CONCLUSIONS: The BCP hybrid scaffold for osteogenesis of MSCs is better than the coralline HA hybrid scaffold by upregulating expression of leptin-R.	hydroxyapatite-beta tricalcium phosphate	17-20	leptin receptor	Oryctolagus cuniculus	140-148
25100662-1	2015	Bone morphology protein-2 (BMP-2) encapsulated chitosan/chondrotin sulfate nanoparticles (CHI/CS NPs) are developed to enhance ectopic bone formation on biphasic calcium phosphate (BCP) scaffolds.	hydroxyapatite-beta tricalcium phosphate	181-184	bone morphogenetic protein 2	Oryctolagus cuniculus	27-32
25709009-2	2015	Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) were coated on the Gel-Pec-BCP surface to investigate of effect of them on bone healing.	hydroxyapatite-beta tricalcium phosphate	110-113	bone morphogenetic protein 2	Rattus norvegicus	0-28
25100662-11	2015	This is because BCP-NP scaffolds harness the intrinsic osteoinductivity BCP and BMP-2, whereas BCP-Dop-NP scaffolds have polydopamine coatings that inhibit the surfaces biological features of BCP scaffolds, and therefore weaken the bone formation ability of scaffolds.	hydroxyapatite-beta tricalcium phosphate	16-19	bone morphogenetic protein 2	Oryctolagus cuniculus	80-85
28787993-4	2015	MG63 cells were used to evaluate cell proliferation and ALP activity on the modified BCP scaffolds.	hydroxyapatite-beta tricalcium phosphate	85-88	ATHS	Homo sapiens	56-59
26436096-1	2015	The purpose of this research was to covalently graft fibroblast growth factor 2 (FGF-2) onto biphasic calcium phosphate (BCP) via a bifunctional cross-linker technique and to estimate the optimal dose of FGF-2 resulting in the best osteogenic differentiation of human mesenchymal stem cells (hMSCs).	hydroxyapatite-beta tricalcium phosphate	121-124	fibroblast growth factor 2	Homo sapiens	53-79
26221587-6	2015	In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone.	hydroxyapatite-beta tricalcium phosphate	64-67	RUNX family transcription factor 2	Homo sapiens	169-174
26221587-6	2015	In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone.	hydroxyapatite-beta tricalcium phosphate	64-67	bone gamma-carboxyglutamate protein	Homo sapiens	181-184
26221587-6	2015	In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone.	hydroxyapatite-beta tricalcium phosphate	64-67	secreted phosphoprotein 1	Homo sapiens	190-193
24889783-5	2015	Furthermore, Smad1, 4, 5, and Dlx5, the main molecules in the BMP/Smads signaling pathway, were upregulated by HA and BCP.	hydroxyapatite-beta tricalcium phosphate	118-121	SMAD family member 1	Homo sapiens	13-18
24889783-5	2015	Furthermore, Smad1, 4, 5, and Dlx5, the main molecules in the BMP/Smads signaling pathway, were upregulated by HA and BCP.	hydroxyapatite-beta tricalcium phosphate	118-121	distal-less homeobox 5	Homo sapiens	30-34
24889783-5	2015	Furthermore, Smad1, 4, 5, and Dlx5, the main molecules in the BMP/Smads signaling pathway, were upregulated by HA and BCP.	hydroxyapatite-beta tricalcium phosphate	118-121	bone morphogenetic protein 2	Homo sapiens	62-65
26436096-1	2015	The purpose of this research was to covalently graft fibroblast growth factor 2 (FGF-2) onto biphasic calcium phosphate (BCP) via a bifunctional cross-linker technique and to estimate the optimal dose of FGF-2 resulting in the best osteogenic differentiation of human mesenchymal stem cells (hMSCs).	hydroxyapatite-beta tricalcium phosphate	121-124	fibroblast growth factor 2	Homo sapiens	81-86
26436096-1	2015	The purpose of this research was to covalently graft fibroblast growth factor 2 (FGF-2) onto biphasic calcium phosphate (BCP) via a bifunctional cross-linker technique and to estimate the optimal dose of FGF-2 resulting in the best osteogenic differentiation of human mesenchymal stem cells (hMSCs).	hydroxyapatite-beta tricalcium phosphate	121-124	fibroblast growth factor 2	Homo sapiens	204-209
26436096-2	2015	SEM observation revealed that the surface of the 100 ng FGF-2 coated BCP was completely covered with the nanoparticles expected to be from the silane coupling agent.	hydroxyapatite-beta tricalcium phosphate	69-72	fibroblast growth factor 2	Homo sapiens	56-61
26436096-4	2015	An MTT assay demonstrated that FGF-2 coated BCP had good biocompatibility, regardless of the concentration of FGF-2, after 24 or 48 h of incubation.	hydroxyapatite-beta tricalcium phosphate	44-47	fibroblast growth factor 2	Homo sapiens	31-36
26436096-5	2015	An alkaline phosphatase (ALP) activity assay (14 days of incubation) and the ALP gene expression level of real-time PCR analysis (7 days of incubation) revealed that 50, 100, and 200 ng FGF-2 coated BCP induced the highest activities among all experimental groups and control group (P < 0.05).	hydroxyapatite-beta tricalcium phosphate	199-202	fibroblast growth factor 2	Homo sapiens	186-191
23651333-1	2014	OBJECTIVES: The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs.	hydroxyapatite-beta tricalcium phosphate	207-210	bone morphogenetic protein 2	Homo sapiens	97-125
24935525-0	2014	In vitro and in vivo studies of BMP-2-loaded PCL-gelatin-BCP electrospun scaffolds.	hydroxyapatite-beta tricalcium phosphate	57-60	bone morphogenetic protein 2	Homo sapiens	32-37
24931105-1	2014	PURPOSE: The objectives of this study were to confirm the osteogenic potential of the Schneiderian membrane and to elucidate the early healing pattern of low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2)-coated biphasic calcium phosphate (BCP).	hydroxyapatite-beta tricalcium phosphate	255-258	bone morphogenetic protein 2	Homo sapiens	181-209
23651333-11	2014	CONCLUSION: Within the limit of this study, it is reasonable to assume that BMP-2-/EGCG-coated biphasic BCP and the newly designed titanium membrane were more beneficial in dehiscence defect healing with increased bone remodeling.	hydroxyapatite-beta tricalcium phosphate	104-107	bone morphogenetic protein 2	Canis lupus familiaris	76-81
23075297-7	2013	It stimulated gene expression of the osteogenic markers core binding factor alpha 1, collagen-1, osteonectin, and osteocalcin in hASCs seeded on BCP and beta-TCP.	hydroxyapatite-beta tricalcium phosphate	145-148	bone gamma-carboxyglutamate protein	Homo sapiens	114-125
23830037-1	2013	OBJECTIVE: The aim of the study was to analyze the value of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) coated biphasic calcium phosphate (BCP) for the obliteration of middle ear bone defect after mastoid surgery.	hydroxyapatite-beta tricalcium phosphate	178-181	bone morphogenetic protein 2	Homo sapiens	103-131
23559460-5	2013	The spherical HA-S and BCP-S particles with abundant micropores and high SSA showed higher adsorption of serum proteins, including fibronectin and vitronectin, than the irregular HA-C did.	hydroxyapatite-beta tricalcium phosphate	23-28	fibronectin 1	Homo sapiens	131-142
23559460-5	2013	The spherical HA-S and BCP-S particles with abundant micropores and high SSA showed higher adsorption of serum proteins, including fibronectin and vitronectin, than the irregular HA-C did.	hydroxyapatite-beta tricalcium phosphate	23-28	vitronectin	Homo sapiens	147-158
23559460-7	2013	Similarly, HA-S and BCP-S particles had a larger amount of the adsorbed BMP-2 per gram solid than HA-C did.	hydroxyapatite-beta tricalcium phosphate	20-25	bone morphogenetic protein 2	Homo sapiens	72-77
23075297-10	2013	In conclusion, 15 min BMP-2 preincubation of hASCs seeded on BCP/beta-TCP scaffolds had a long-lasting stimulating effect on osteogenic differentiation in vitro.	hydroxyapatite-beta tricalcium phosphate	61-64	bone morphogenetic protein 2	Homo sapiens	22-27
22733619-1	2012	Block-type biphasic calcium phosphate (BCP) carriers are more effective at delivering recombinant human bone morphogenetic protein-2 (rhBMP-2) in various clinical situations than are particle-type carriers, due to their potential for highly successful three-dimensional bone regeneration.	hydroxyapatite-beta tricalcium phosphate	39-42	bone morphogenetic protein 2	Homo sapiens	104-132
22729020-3	2012	Porous BCP nanoceramics showed higher ability to adsorb proteins, especially low molecular weight protein of LSZ, than conventional BCP ceramics, and the BCP nanoceramics promoted bone sialoprotein expression more than conventional BCP did.	hydroxyapatite-beta tricalcium phosphate	7-10	lysozyme	Homo sapiens	109-112
22774411-7	2012	PRP and MSC used in combination with BCP as a defect filling resulted in greater osteoblastic bone formation activity when compared to the use of BCP alone.	hydroxyapatite-beta tricalcium phosphate	146-149	proline rich protein 2-like 1	Rattus norvegicus	0-3
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	hydroxyapatite-beta tricalcium phosphate	24-27	integrin subunit alpha 2	Homo sapiens	103-118
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	hydroxyapatite-beta tricalcium phosphate	24-27	mitogen-activated protein kinase 1	Homo sapiens	126-163
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	hydroxyapatite-beta tricalcium phosphate	24-27	mitogen-activated protein kinase 1	Homo sapiens	165-168
21316494-7	2011	We demonstrated that 5x10(-5)M SrCl(2) and BCP(5%) increased the expression of type I collagen and SERPINH1 mRNA and reduced the production of matrix metalloproteinases (MMP-1 and MMP-2) without modifying the levels of the tissue inhibitors of MMPs (TIMPs).	hydroxyapatite-beta tricalcium phosphate	43-46	matrix metallopeptidase 1	Homo sapiens	170-175
21316494-7	2011	We demonstrated that 5x10(-5)M SrCl(2) and BCP(5%) increased the expression of type I collagen and SERPINH1 mRNA and reduced the production of matrix metalloproteinases (MMP-1 and MMP-2) without modifying the levels of the tissue inhibitors of MMPs (TIMPs).	hydroxyapatite-beta tricalcium phosphate	43-46	serpin family H member 1	Homo sapiens	99-107
21316494-7	2011	We demonstrated that 5x10(-5)M SrCl(2) and BCP(5%) increased the expression of type I collagen and SERPINH1 mRNA and reduced the production of matrix metalloproteinases (MMP-1 and MMP-2) without modifying the levels of the tissue inhibitors of MMPs (TIMPs).	hydroxyapatite-beta tricalcium phosphate	43-46	matrix metallopeptidase 2	Homo sapiens	180-185
21316494-7	2011	We demonstrated that 5x10(-5)M SrCl(2) and BCP(5%) increased the expression of type I collagen and SERPINH1 mRNA and reduced the production of matrix metalloproteinases (MMP-1 and MMP-2) without modifying the levels of the tissue inhibitors of MMPs (TIMPs).	hydroxyapatite-beta tricalcium phosphate	43-46	matrix metallopeptidase 1	Homo sapiens	244-248
21442744-3	2011	Biphasic calcium phosphates (BCPs) composed of both HAp and beta-TCP have controlled degradation to some extent.	hydroxyapatite-beta tricalcium phosphate	29-33	retinoic acid receptor beta	Homo sapiens	52-55
21442744-4	2011	Here, we have prepared three different BCPs composed of beta-TCP and HAp.	hydroxyapatite-beta tricalcium phosphate	39-43	retinoic acid receptor beta	Homo sapiens	56-72
27877290-5	2009	Sixteen weeks after the implantation, more alkaline-phosphatase-positive cells were observed in the pores of hydroxyapatite and BCP, and the expression of the osteocalcin gene (an osteoblast-specific marker) in tissue grown in pores was also higher in hydroxyapatite and BCP than in beta-TCP.	hydroxyapatite-beta tricalcium phosphate	271-274	bone gamma-carboxyglutamate protein	Rattus norvegicus	159-170
19857608-4	2010	The experimental results showed that BCP always had a higher ability to adsorb fibrinogen, insulin or type I collagen (Col-I) than HA.	hydroxyapatite-beta tricalcium phosphate	37-40	insulin	Homo sapiens	91-98
19857608-6	2010	HA and BCP particles with higher microporosities and/or more micropores >20 nm in diameter could adsorb more fibrinogen or insulin.	hydroxyapatite-beta tricalcium phosphate	7-10	insulin	Homo sapiens	126-133
20178096-4	2010	We hypothesized that a continuous delivery of low concentrations of VEGF from calcium phosphate ceramics may increase the efficacy of VEGF administration.VEGF was co-precipitated onto biphasic calcium phosphate (BCP) ceramics to achieve a sustained release of the growth factor.	hydroxyapatite-beta tricalcium phosphate	212-215	vascular endothelial growth factor A	Mus musculus	68-72
20178096-10	2010	Furthermore, a sustained, cell-mediated release of low concentrations of VEGF from BCP ceramics was mediated by resorbing osteoclasts.	hydroxyapatite-beta tricalcium phosphate	83-86	vascular endothelial growth factor A	Mus musculus	73-77
20189819-2	2010	The aim of the present study was to evaluate whether bone morphogenetic protein (BMP-7) promoted osteoinduction could be enhanced by combining it with vascular endothelial growth factor (VEGF) or MSCs in highly porous biphasic calcium phosphate (BCP) ceramics.	hydroxyapatite-beta tricalcium phosphate	246-249	bone morphogenetic protein 7	Mus musculus	81-86